Released Aug 13, 2020, after the close
10-Q filed Aug 13, 2020, 44 days after period end · 0001390478-20-000026
Q2 2020 · 10-Q
Revenue$0.00$0.00 no prior Q2 2019 on fileno prior Q1 2020 on file
Net Income-$4.43M-$4.43M N/M vs Q2 2019N/M vs Q1 2020
EPS Diluted-$0.66-$0.66 N/M vs Q2 2019N/M vs Q1 2020
Operating Income-$4,267,000—
Operating Cash Flowderived-$3,381,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2020 | Q2 2019 | Q2 2018 | Q2 2017 |
|---|---|---|---|---|
| Revenue | $0.00 | — | — | — |
| Net Income | -$4.43M | -$3.13M | -$6.06M | -$5.91M |
| EPS Diluted | -$0.66 | -$6.33 | -$1.26 | -$0.22 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR